CytoMed Therapeutics Limited (GDTC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CytoMed Therapeutics Limited has released its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2023 and 2024, revealing a loss for the period. The company experienced a decrease in total comprehensive loss from S$2,224,461 in 2023 to S$1,083,150 in 2024, with corresponding losses per share of S$0.22 and S$0.09 respectively. Key financial figures include research expenses and other operating losses, alongside revenue and operating income data for the concerned periods.
For further insights into GDTC stock, check out TipRanks’ Stock Analysis page.